Compare Banco Santander SA (SAN) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Santander SA vs Zimmer Biomet Holdings Inc — how do they compare? Banco Santander SA trades at $13.44 (market cap $192.86B), while Zimmer Biomet Holdings Inc trades at $89.08 (market cap $16.95B). The key difference: Banco Santander SA is far larger — about 11.4× Zimmer Biomet Holdings Inc's market cap, and Banco Santander SA pays the higher dividend (2.06%). Which is the better fit depends on your goals — on Pluang, investors hold Banco Santander SA for 55 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| SAN | ZBH | |
|---|---|---|
Market Cap | $192.86B | $16.95B |
Volume | 10,644,519 | 2,505,240 |
Sector | Financials | Health |
52-Week High | $15.05 | $103.98 |
52-Week Low | $9.65 | $79.58 |
Typical Hold Time | 55 Days | 89 Days |
Enterprise Value | $360.86B | $24.02B |
Dividend Yield | 2.06% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Banco Santander (SAN) trades at $13.66, down 2.5% today, with technical indicators showing bearish momentum. The company reported strong fundamentals with Q2 2026 net income of $14.10 billion and a 26.25% net margin, though cash flow trends show recent operational challenges. Recent developments include the completion of the Webster Financial acquisition, expanding Santander's U.S. presence and diversification.
Outlook remains mixed with analyst consensus at 'Moderate Buy' (64% buy ratings) but technical weakness. Key opportunities include record profitability and strategic acquisitions, while risks involve declining cash flows and high debt levels. The stock's valuation appears reasonable with P/E of 13.55 and P/B of 1.58.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
